Rockland Immunochemicals, Inc. (Rockland) announces the availability of a new collection of human melanoma cell lines that have been developed and characterized over several decades in the laboratory of Meenhard Herlyn, D.V.M., D.Sc., Caspar Wistar Professor in Melanoma Research, Director of the Melanoma Research Center, and professor in the Molecular and Cellular Oncogenesis Program at The Wistar Institute in Philadelphia. More than one hundred of these human melanoma cell lines will now be grown and exclusively distributed by Rockland. This new agreement results from a partnership between the institutions, which was announced in July 2015.

The collection represents a diverse panel of highly-characterized cell lines. Historically, a number of tumor model systems have lacked scientific value due to the limited characterization of genetic drivers, gene and protein expression, and in vitro/in vivo data. With these human melanoma cell lines, in vitro and in vivo modeling is brought into practice. The...

In a multimedia video produced by Rockland, Herlyn describes the importance of the collection of human melanoma cell lines to best reflect the complicated and complex environment in which melanoma exists, to better analyze and determine the stages of melanoma progression and metastasis in patients, and to ultimately advance cancer research throughout the world.

“We need models because we cannot do everything in patients,” said Herlyn. “We need to make sure that our models reflect what’s going on in patients. That’s why we have the cell lines, they are our work horses and without them we could not do what we do.”

In the video, Herlyn and Carl Ascoli, Ph.D., Chief Science Officer at Rockland, discuss innovative practices to recreate individual cells from a sample of a patient’s original skin and the critical cell culture conditions and rigorous validation that Rockland performs to ensure their integrity. Meenhard Herlyn, D.V.M., D.Sc. (The Wistar Institute) and Carl Ascoli, Ph.D. (Rockland Immunochemicals, Inc.)

“We are really excited to be able to bring such impactful products to the market,” said Richard Smith, Chief Operating Officer at Rockland. “We take very seriously our responsibility to ensure the quality and integrity of all of our products. These human melanoma cell lines not only enhance cancer research by bridging the gap between patient and laboratory samples, but set the bar extremely high for more collaborations to come.”

Rockland Immunochemicals, Inc. supports the academic, biopharma, and diagnostic industries with antibodies and antibody based tools used in basic research, assay development, and preclinical studies. With facilities in Pennsylvania for over 50 years, Rockland manufactures products ideally suited for integration into critical assays such as western blotting, immunohistochemistry (IHC), immunofluorescence microscopy (IF), ELISA and flow cytometry.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?